ImmunogenX  Developing advanced diagnostics to relieve suffering from food allergens
  • About
  • Science
  • Patients
  • News and Events
  • Contact
the header image

Latiglutenase Therapy

Latiglutenase is a mixture of recombinant proteases that degrade gluten proteins in the stomach rendering them physiologically inactive. The drug has been extensively studied in Phase 2a and 2b clinical trials where it has demonstrated protection of intestinal mucosal injury and symptomatic improvement in CD patients.

CypCel Diagnostics

For disease management we are running a new clinical study following a proof of concept study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing gluten-free diet treatment. This is a unique capability for which there are no other effective diagnostics.

Gluten Proteomics

For food safety we are pioneering advanced methods to identify new physiologically relevant gluten peptide sequences in wheat, barley, and rye grain to greatly improve on the capability to screen for the full range of gluten proteins in food products.

News Highlights

Co-founder of ImmunogenX hopes to help others with celiac disease by developing treatments for the disease (March 2023)

ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology (August 2022)

ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference (May 2022)

ImmunogenX to Make Highlighted Presentations at DDW 2022 (February 2022)

Jennifer Sealey-Voyksner Special Guest for Beyond Celiac Blog Series (December 2021)

More News
  • About
  • Science
  • Patients
  • News and Events
  • Contact

Copyright © 2021 ImmunogenX, Inc.